TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3698751

Group type: EXPERIMENTAL
Intervention: Long intestinal (Cantor) tube preoperatively
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Nasogastric tube placed intraoperatively
Number of subjects: 138

Group type: COMPARATOR
Intervention: No gastrointestinal tube at all
Number of subjects: 138
Study: 31669738

Group type: EXPERIMENTAL
Intervention: Enhanced recovery after surgery
Number of subjects: 118

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 118
Study: 29331328

Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula (HFNC) oxygen therapy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Conventional oxygen therapy (control)
Number of subjects: 62
Study: 28440216

Group type: EXPERIMENTAL
Intervention: Transseptal suturing
Number of subjects: 62

Group type: COMPARATOR
Intervention: Nasal packing
Number of subjects: 62
Study: 24608960

Group type: EXPERIMENTAL
Intervention: Efavirenz 600 mg daily
Number of subjects: 540
Study: 23022104

Group type: EXPERIMENTAL
Intervention: 0.1 M, pH 1.0 HCl
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.1 N, pH 13.0 NaOCl
Number of subjects: 90

Group type: COMPARATOR
Intervention: Deionized water (pH 6.9)
Number of subjects: 90
Study: 21351264

Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment
Number of subjects: 328

Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 328
Study: 18051216

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with a high-dose, standardized, 3-grass pollen extract
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 16087920

Group type: EXPERIMENTAL
Intervention: Levodopa (single oral dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10930797

Group type: EXPERIMENTAL
Intervention: Paclitaxel
Number of subjects: 187

Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 187
Study: 9305335

Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg/d
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg/d
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Gabapentin 2400 mg/d
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Gabapentin (all dosages combined)
Number of subjects: 275
Study: 8339575

Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 58

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 58
Study: 30509271

Group type: EXPERIMENTAL
Intervention: Empagliflozin (25 mg daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Metformin (2000 mg daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Empagliflozin/Metformin (25 mg and 2000 mg daily, respectively)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 26751068

Group type: EXPERIMENTAL
Intervention: H2025A (infant formula fortified with DHA and ARA, DHA/ARA ratio of 2:1)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control formula (infant formula fortified only with DHA)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: H2025A
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 35
Study: 23086332

Group type: EXPERIMENTAL
Intervention: Vertise Flow (VF, Kerr)
Number of subjects: 32

Group type: COMPARATOR
Intervention: G-Bond (GB, GC)
Number of subjects: 32

Group type: COMPARATOR
Intervention: AdheSE One (AO, Ivoclar Vivadent)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Adper Easy Bond (EB, 3M ESPE)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Xeno V (XV, Dentsply)
Number of subjects: 32

Group type: COMPARATOR
Intervention: iBOND (iB, Heraeus Kulzer)
Number of subjects: 32
Study: 21946199

Group type: EXPERIMENTAL
Intervention: Conventional therapy + anti-Helicobacter pylori therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study: 18455083

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16269526

Group type: EXPERIMENTAL
Intervention: Jump training (10 maximum vertical jumps/day, 3 times/week for 6 months)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 12673718

Group type: EXPERIMENTAL
Intervention: CD38 high expression (> or = 20%)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CD38 low expression (< 20%) with low CD31 expression (< 76%)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CD38 low expression (< 20%) with high CD31 expression
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CD31 expression
Number of subjects: 120
Study: 10868867

Group type: EXPERIMENTAL
Intervention: Active PENS treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 50
Study: 9568325

Group type: EXPERIMENTAL
Intervention: Active phase hypertrophic scars
Number of subjects: 0

Group type: COMPARATOR
Intervention: Remission phase hypertrophic scars
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normotrophic scars
Number of subjects: 0
Study: 8173690

Group type: EXPERIMENTAL
Intervention: Felodipine-metoprolol combination tablet (extended-release), administered once daily, dosage individually titrated until blood pressure control achieved.
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Felodipine-metoprolol combination tablet (extended-release) for 24 months (Swedish/UK study).
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Felodipine-metoprolol combination tablet (extended-release) with hydrochlorothiazide added if necessary (12.5 or 25 mg daily).
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Felodipine-metoprolol combination tablet (extended-release).
Number of subjects: 337
Study: 3325175

Group type: EXPERIMENTAL
Intervention: amikacin + ceftazidime
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: amikacin + aztreonam
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: amikacin + piperacillin
Number of subjects: 60
Study: 30122799

Group type: EXPERIMENTAL
Intervention: Bridges (1:1 savings match)
Number of subjects: 1383

Group type: EXPERIMENTAL
Intervention: Bridges PLUS (1:2 savings match)
Number of subjects: 1383

Group type: EXPERIMENTAL
Intervention: Bridges and Bridges PLUS
Number of subjects: 1383

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1383
Study: 26908839

Group type: EXPERIMENTAL
Intervention: Gonadotropin suppression (testosterone enanthate + GnRH antagonist acyline)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Gonadotropin suppression (testosterone enanthate + progestin levonorgestrel)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Gonadotropin suppression (testosterone enanthate + levonorgestrel + GnRH antagonist acyline)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Gonadotropin suppression (testosterone enanthate + levonorgestrel + 5α‐reductase inhibitor dutasteride)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (7 men)
Number of subjects: 22
Study: 24509717

Group type: EXPERIMENTAL
Intervention: Accurate instructions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inaccurate instructions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pliance instructions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tracking instructions
Number of subjects: 0
Study: 23358784

Group type: EXPERIMENTAL
Intervention: Managed Problem Solving (MAPS)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 180
Study: 20586934

Group type: EXPERIMENTAL
Intervention: Entecavir 0.5 mg/day
Number of subjects: 519

Group type: COMPARATOR
Intervention: Lamivudine 100 mg/day
Number of subjects: 519
Study: 18380628

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pravastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 0
Study: 20688040

Group type: EXPERIMENTAL
Intervention: LEISH-F1+MPL-SE vaccine (5, 10, or 20 μg recombinant Leishmania polyprotein LEISH-F1 antigen + 25 μg MPL-SE adjuvant)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: LEISH-F1+MPL-SE vaccine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Adjuvant alone
Number of subjects: 44

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 44
Study: 16118921

Group type: EXPERIMENTAL
Intervention: Phacotrabeculectomy from single incision
Number of subjects: 41

Group type: COMPARATOR
Intervention: Phacotrabeculectomy and phacoemulsification from two separate incisions
Number of subjects: 41
Study: 12127611

Group type: EXPERIMENTAL
Intervention: Ir-192
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Ir-192 (Diabetic patients)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Ir-192 (Nondiabetic patients)
Number of subjects: 252
Study: 9494881

Group type: EXPERIMENTAL
Intervention: Combined weight and cycle training
Number of subjects: 23

Group type: COMPARATOR
Intervention: Cycle training
Number of subjects: 23
Study: 7531487

Group type: EXPERIMENTAL
Intervention: Vinorelbine (30 mg/m2 i.v. bolus weekly)
Number of subjects: 24
Study: 3062535

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser treatment
Number of subjects: 43

Group type: COMPARATOR
Intervention: Argon laser treatment
Number of subjects: 43
Study: 29580746

Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study: 26928845

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel daily for 14 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo gel daily for 14 weeks
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel
Number of subjects: 64
Study: 25344483

Group type: EXPERIMENTAL
Intervention: e-learning
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: classroom teaching
Number of subjects: 183
Study: 23118021

Group type: EXPERIMENTAL
Intervention: Low-dose MDMA (25 mg, plus 12.5 mg supplemental dose)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Full-dose MDMA (125 mg, plus 62.5 mg supplemental dose)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Three MDMA sessions
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (active-placebo)
Number of subjects: 12
Study: 20844457

Group type: EXPERIMENTAL
Intervention: Eccentric-concentric load of 60-40 kg (40 kg concentric with additional 20 kg eccentric)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Eccentric-concentric load of 70-40 kg (40 kg concentric with additional 30 kg eccentric)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Eccentric-concentric load of 80-40 kg (40 kg concentric with additional 40 kg eccentric)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Eccentric-concentric load of 40-40 kg (equated load condition)
Number of subjects: 14
Study: 19043158

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 16848349

Group type: EXPERIMENTAL
Intervention: Group A (normal radiographic and scintigraphic examinations)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group B (diffusely increased uptake)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group C (pathology revealed by radiography and scintigraphy)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Group D (knee-healthy controls)
Number of subjects: 80
Study: 12839713

Group type: EXPERIMENTAL
Intervention: Immunoglobulin concentrate-supplemented infant formula
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control formula (non-supplemented)
Number of subjects: 125
Study: 10440423

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg in fasting state
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg in fed state
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg with antacid (Maalox 2 x 400 mg tablets 1 hour before dosing)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg without antacid
Number of subjects: 24
Study: 8558205

Group type: EXPERIMENTAL
Intervention: Buthionine sulfoximine (BSO) 1.5 to 17 g/m2 intravenously every 12 hours for six doses, followed by melphalan (L-PAM) 15 mg/m2 intravenously 1 hour after the fifth dose of BSO in the second cycle.
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Buthionine sulfoximine (BSO) at doses >= 13 g/m2.
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Buthionine sulfoximine (BSO) at various doses.
Number of subjects: 41
Study: 1805152

Group type: EXPERIMENTAL
Intervention: 1 mg vitamin K1 intramuscularly
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no vitamin K1)
Number of subjects: 12
Study: 6125195

Group type: EXPERIMENTAL
Intervention: 5 mg pindolol
Number of subjects: 30

Group type: COMPARATOR
Intervention: 100 mg metoprolol
Number of subjects: 30
Study: 31246882

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy for Insomnia (CBT-I) for 6 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 24
Study: 29493402

Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone Easyhaler (two inhalations of 50/500 μg/inhalation strength)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone Easyhaler
Number of subjects: 65

Group type: COMPARATOR
Intervention: Seretide® Diskus® DPI (reference product)
Number of subjects: 65
Study: 25892407

Group type: EXPERIMENTAL
Intervention: No-sedation
Number of subjects: 140

Group type: COMPARATOR
Intervention: Sedation with daily wake up
Number of subjects: 140
Study: 24923533

Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment (CGA) conducted by a geriatrician before cancer treatment, participation of the same geriatrician in cancer treatment selection, a standardised geriatric therapeutic intervention designed by the same geriatrician, and geriatric follow-up for 24 months.
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment (CGA)
Number of subjects: 704
Study: 22934526

Group type: EXPERIMENTAL
Intervention: Shengjing prescription
Number of subjects: 120

Group type: COMPARATOR
Intervention: Vitamin E (Control)
Number of subjects: 120
Study: 20231191

Group type: EXPERIMENTAL
Intervention: Clinical decision support (CDS) embedded in the electronic health record (EHR)
Number of subjects: 12
Study: 18754979

Group type: EXPERIMENTAL
Intervention: Parish Nurse Intervention Program (n=49)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Care As Usual (n=51)
Number of subjects: 100
Study: 16033354

Group type: EXPERIMENTAL
Intervention: Nebulized vitamin B12
Number of subjects: 23

Group type: COMPARATOR
Intervention: 0.02% vitamin B12 eye drops
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 23
Study: 15258534

Group type: EXPERIMENTAL
Intervention: Assisted hatching (mechanical, chemical, laser beam, piezoelectric method)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assisted hatching
Number of subjects: 0
Study: 11598983

Group type: EXPERIMENTAL
Intervention: Interventions included education and voluntary medical surveillance in 1994; substitution of low protein, 'powder-free' NRL gloves for non-sterile powdered gloves in 1995; replacement of powdered sterile NRL gloves by lower protein, 'powder-free' NRL gloves in 1997.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Glove changes and latex policies instituted by hospitals.
Number of subjects: 60
Study: 9065537

Group type: EXPERIMENTAL
Intervention: NSAID use (2 or more years)
Number of subjects: 1686

Group type: COMPARATOR
Intervention: NSAID use (less than 2 years)
Number of subjects: 1686

Group type: COMPARATOR
Intervention: Aspirin use
Number of subjects: 1686

Group type: COMPARATOR
Intervention: Acetaminophen use
Number of subjects: 1686
Study: 8145097

Group type: EXPERIMENTAL
Intervention: Higher potency pancreatic enzyme preparations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme preparations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fecal energy loss
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro enzyme potency
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher potency preparations
Number of subjects: 0
Study: 3463271

Group type: EXPERIMENTAL
Intervention: Spar-Cal
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Calcium Sandoz
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Os-Cal
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ossopan
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Calcium supplements (1 gram of elemental calcium)
Number of subjects: 10
Study: 30290615

Group type: EXPERIMENTAL
Intervention: Closed-loop target-controlled infusion of propofol and remifentanil
Number of subjects: 204

Group type: COMPARATOR
Intervention: Manual target-controlled infusion of propofol and remifentanil
Number of subjects: 204
Study: 26929604

Group type: EXPERIMENTAL
Intervention: Xuanbai Chengqi decoction
Number of subjects: 53

Group type: COMPARATOR
Intervention: Conventional treatment and lung-protective ventilation strategy
Number of subjects: 53
Study: 23858525

Group type: EXPERIMENTAL
Intervention: Train‐the‐trainer programme 'Fit for Shared Decision‐Making'
Number of subjects: 402

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 402
Study: 22839709

Group type: EXPERIMENTAL
Intervention: ω-3 polyunsaturated fatty acids (PUFA) 1 g/day for 6 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (standard antiarrhythmic therapy without ω-3 PUFA)
Number of subjects: 80
Study: 20346242

Group type: EXPERIMENTAL
Intervention: Combination DMARD therapy (COMBI) starting with sulfasalazine, methotrexate, hydroxychloroquine, and prednisolone
Number of subjects: 195

Group type: COMPARATOR
Intervention: Monotherapy (SINGLE) initially with sulfasalazine, with or without prednisolone
Number of subjects: 195
Study: 19067892

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC, 30-45 mg/kg/d)
Number of subjects: 10

Group type: COMPARATOR
Intervention: L-alanine
Number of subjects: 10
Study: 16188807

Group type: EXPERIMENTAL
Intervention: Nebulization of 0.25 mg dexamethasone every 6 hours (group 1)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Nebulization of 0.9% saline (group 2)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Subgroup of prematurely born children in group 1
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both groups (group 1 and group 2)
Number of subjects: 61
Study: 14519708

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (0.625 mg conjugated equine estrogens plus 2.5 mg medroxyprogesterone acetate)
Number of subjects: 16608

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16608
Study: 10561249

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) 20 mg/d for 4 years plus Epirubicin (EPI) 50 mg/m² intravenously on days 1 and 8 every 4 weeks for six cycles
Number of subjects: 604

Group type: COMPARATOR
Intervention: Tamoxifen (TAM) 20 mg/d for 4 years
Number of subjects: 604
Study: 8751014

Group type: EXPERIMENTAL
Intervention: Ketoprofen 50 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ketoprofen 150 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 2164193

Group type: EXPERIMENTAL
Intervention: Cisplatin/Vepesid
Number of subjects: 150

Group type: COMPARATOR
Intervention: Endoxan/Vepesid
Number of subjects: 150
Study: 400734

Group type: EXPERIMENTAL
Intervention: Intravenous administration of regular insulin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30644283

Group type: EXPERIMENTAL
Intervention: WALANT (Wide Awake Local Anaesthesia Without Tourniquet)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Loco-regional anaesthesia with tourniquet
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: WALANT
Number of subjects: 60
Study: 27052787

Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with nuts and pharmacological treatment
Number of subjects: 50
Study: 24931748

Group type: EXPERIMENTAL
Intervention: Homeopathic treatment plus usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supportive listening plus usual care
Number of subjects: 0
Study: 22804250

Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.5 mg
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.0 mg
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.1 mg
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: All dulaglutide doses
Number of subjects: 167
Study: 20410085

Group type: EXPERIMENTAL
Intervention: DAG oil (40 g/d)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control oil (40 g/d)
Number of subjects: 26
Study: 18481239

Group type: EXPERIMENTAL
Intervention: Resection (n = 20)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Transection (n = 20)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ablation (n = 20)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Clipping (n = 20)
Number of subjects: 80

Group type: COMPARATOR
Intervention: All techniques
Number of subjects: 80
Study: 16393757

Group type: EXPERIMENTAL
Intervention: Eye movement measures for reading speed
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Neurocognitive assessment
Number of subjects: 1
Study: 14686231

Group type: EXPERIMENTAL
Intervention: Universal prophylaxis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective prophylaxis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preemptive therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment of active disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CMV immune globulin i.v.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral acyclovir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valacyclovir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral valganciclovir
Number of subjects: 0